Latest news
Tirzepatide’s Next Question: What Lies Beyond Cardiovascular Events?
New SURPASS-CVOT analyses presented at EASD 2026 suggest that tirzepatide may offer benefits beyond conventional cardiovascular endpoints, including lower infection-related mortality and better patient-reported physical functioning compared with dulaglutide.
Gut bacteria could help explain how vegetable-rich diets protect cardiometabolic health
Cancer Survivorship Standards Are Still Mostly Paper
MS Prevention Is Still Too Passive
Europe Has The Mosquitoes. Not The Tools.
Four in five young adults in an urban U.S. cohort had CKM risk factors. Cardiovascular prevention is arriving too late
Coffee drinkers had less visceral fat despite similar BMI. The finding exposes what the scale misses
IPM Brief – Issue 23 | The white coat has a passport
Breast Cancer Immunotherapy Has a New Problem: Who Gets the Second Checkpoint?
Down Syndrome Cannot Be Alzheimer’s Afterthought
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.